Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CYP2D6 GENE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 54 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Wennerholm, A; Johansson, I; Hidestrand, M; Bertilsson, L; Gustafsson, LL; Ingelman-Sundberg, M
      Characterization of the CYP2D6*29 allele commonly present in a blade Tanzanian population causing reduced catalytic activity

      PHARMACOGENETICS
    2. Slanar, O; Perlik, F; Jirasek, V
      Phenotype of cytochrome P450CYP2D6 in patients with familial adenomatous polyposis

      METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY
    3. Ingelman-Sundberg, M
      Genetic variability in susceptibility and response to toxicants

      TOXICOLOGY LETTERS
    4. Kvist, EE; Al-Shurbaji, A; Dahl, ML; Nordin, C; Alvan, G; Stahle, L
      Quantitative pharmacogenetics of nortriptyline - A novel approach

      CLINICAL PHARMACOKINETICS
    5. Eap, CB; Broly, F; Mino, A; Hammig, R; Deglon, JJ; Uehlinger, C; Meili, D; Chevalley, AF; Bertschy, G; Zullino, D; Kosel, M; Preisig, M; Baumann, P
      Cytochrome P450 2D6 genotype and methadone steady-state concentrations

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    6. Carlsson, B; Olsson, G; Reis, M; Walinder, J; Nordin, C; Lundmark, J; Scordo, MG; Dahl, ML; Bengtsson, F; Ahlner, J
      Enantioselective analysis of citalopram and metabolites in adolescents

      THERAPEUTIC DRUG MONITORING
    7. Steimer, W; Muller, B; Leucht, S; Kissling, W
      Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy

      CLINICA CHIMICA ACTA
    8. Williams, DG; Hatch, DJ; Howard, RF
      Codeine phosphate in paediatric medicine

      BRITISH JOURNAL OF ANAESTHESIA
    9. Flockhart, DA; Oesterheld, JR
      Cytochrome P450-mediated drug interactions

      CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA
    10. Murphy, MP; Beaman, ME; Clark, LS; Cayouette, M; Benson, L; Morris, DM; Polli, JW
      Prospective GYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial

      PHARMACOGENETICS
    11. Lo-Guidice, JM; Allorge, D; Chevalier, D; Debuysere, H; Fazio, F; Lafitte, JJ; Broly, F
      Molecular analysis of the N-acetyltransferase 1 gene (NAT1*) using polymerase chain reaction-restriction fragment-single strand conformation polymorphism assay

      PHARMACOGENETICS
    12. Isaza, CA; Henao, J; Lopez, AM; Cacabelos, R
      Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population

      METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY
    13. Chou, WH; Yan, FX; de Leon, J; Barnhill, J; Rogers, T; Cronin, M; Pho, M; Xiao, V; Ryder, TB; Liu, WW; Teiling, C; Wedlund, PJ
      Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    14. Maiorova, OA; Zeeger, K; Rumyantsev, AG
      Genetic polymorphism of enzymes involved in drug metabolism and its role in carcinogenesis

      GEMATOLOGIYA I TRANSFUZIOLOGIYA
    15. Hersberger, M; Marti-Jaun, J; Rentsch, K; Hanseler, E
      Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR

      CLINICAL CHEMISTRY
    16. Hijikata, M; Miyakawa, H; Matsushita, M; Kako, M; Ohta, Y; Mishiro, S
      CYP2D6 polymorphism and the presence of anti-LKM-1 in patients with chronic hepatitis C

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    17. Dettling, M; Sachse, C; Brockmoller, J; Schley, J; Muller-Oerlinghausen, B; Pickersgill, I; Rolfs, A; Schaub, RT; Schmider, J
      Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients

      PSYCHOPHARMACOLOGY
    18. Weber, WW
      Populations and genetic polymorphisms

      MOLECULAR DIAGNOSIS
    19. Linder, MW; Valdes, R
      Pharmacogenetics in the practice of laboratory medicine

      MOLECULAR DIAGNOSIS
    20. Dalen, P; Dahl, ML; Eichelbaum, M; Bertilsson, L; Wilkinson, GR
      Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes

      PHARMACOGENETICS
    21. Vorhees, CV; Morford, LL; Inman, SL; Reed, TM; Schilling, MA; Cappon, GD; Moran, MS; Nebert, DW
      Genetic differences in spatial learning between Dark Agouti and Sprague-Dawley strains: Possible correlation with the CYP2D2 polymorphism in rats treated neonatally with methamphetamine

      PHARMACOGENETICS
    22. Ingelman-Sundberg, M
      Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: Evolutionary, toxicological, and clinical pharmacological aspects

      DRUG METABOLISM REVIEWS
    23. Coutts, RT; Urichuk, LJ
      Polymorphic cytochromes P450 and drugs used in psychiatry

      CELLULAR AND MOLECULAR NEUROBIOLOGY
    24. Linder, MW; Valdes, R
      Fundamentals and applications of pharmacogenetics for the clinical laboratory

      ANNALS OF CLINICAL AND LABORATORY SCIENCE
    25. Nicholl, DJ; Bennett, P; Hiller, L; Bonifati, V; Vanacore, N; Fabbrini, G; Marconi, R; Colosimo, C; Lamberti, P; Stocchi, F; Bonuccelli, U; Vieregge, P; Ramsden, DB; Meco, G; Williams, AC
      A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders

      NEUROLOGY
    26. Aynacioglu, AS; Sachse, C; Bozkurt, A; Kortunay, S; Nacak, M; Schroder, T; Kayaalp, SO; Roots, I; Brockmoller, J
      Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6in the Turkish population

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    27. Marsh, JCW; Chowdry, J; Parry-Jones, N; Ellis, SW; Muir, KR; Gordon-Smith, EC; Tucker, GT
      Study of the association between cytochromes P450 2D6 and 2E1 genotypes and the risk of drug and chemical induced idiosyncratic aplastic anaemia

      BRITISH JOURNAL OF HAEMATOLOGY
    28. Nelson, DR
      Cytochrome P450 and the individuality of species

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    29. Ingelman-Sundberg, M; Oscarson, M; McLellan, RA
      Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

      TRENDS IN PHARMACOLOGICAL SCIENCES
    30. Scordo, MG; Spina, E; Facciola, G; Avenoso, A; Johansson, I; Dahl, ML
      Cytochrome P450 2D6 genotype and steady state plasma levels of risperidoneand 9-hydroxyrisperidone

      PSYCHOPHARMACOLOGY
    31. SACHSE C; BROCKMOLLER J; HILDEBRAND M; MULLER K; ROOTS I
      CORRECTNESS ELF PREDICTION OF THE CYP2D6 PHENOTYPE CONFIRMED BY GENOTYPING 47 INTERMEDIATE AND POOR METABOLIZERS OF DEBRISOQUINE

      Pharmacogenetics
    32. PANG CP; ZHANG J; WOO J; CHAN D; LAW LK; TONG SF; KWOK T; KAY R
      RARITY OF DEBRISOQUINE HYDROXYLASE GENE POLYMORPHISM IN CHINESE PATIENTS WITH PARKINSONS-DISEASE

      Movement disorders
    33. Ingelman-Sundberg, M
      Functional consequences of polymorphism of xenobiotic metabolising enzymes

      TOXICOLOGY LETTERS
    34. NORMANN C; HESSLINGER B; BAUER J; BERGER M; WALDEN J
      THE ROLE OF THE HEPATIC CYTOCHROME-P450 ENZYMES IN PSYCHOPHARMACOLOGY

      Nervenarzt
    35. LADERO JM; GARCIAAGUNDEZ JA; BENITEZ J
      ENZYMATIC POLYMORPHISMS AND LUNG-CANCER

      Medicina Clinica
    36. AGUNDEZ JAG; MARTINEZ C; OLIVERA M; GALLARDO L; LADERO JM; ROSADO C; PRADOS J; RODRIGUEZMOLINA J; RESEL L; BENITEZ J
      EXPRESSION IN HUMAN PROSTATE OF DRUG-METABOLIZING AND CARCINOGEN-METABOLIZING ENZYMES - ASSOCIATION WITH PROSTATE-CANCER RISK

      British Journal of Cancer
    37. ELZEIN R; ZWISCHENBERGER JB; WOOD TG; ABDELRAHMAN SZ; BREKELBAUM C; AU WW
      COMBINED GENETIC-POLYMORPHISM AND RISK FOR DEVELOPMENT OF LUNG-CANCER

      Mutation research. Fundamental and molecular mechanisms of mutagenesis
    38. SHULMAN RW; OZDEMIR V
      PSYCHOTROPIC MEDICATIONS AND CYTOCHROME-P450 2D6 PHARMACOKINETIC CONSIDERATIONS IN THE ELDERLY

      Canadian journal of psychiatry
    39. YUE QY; ALM C; SVENSSON JO; SAWE J
      QUANTIFICATION OF THE O-DEMETHYLATED AND N-DEMETHYLATED AND THE GLUCURONIDATED METABOLITES OF CODEINE RELATIVE TO THE DEBRISOQUINE METABOLIC RATIO IN URINE IN ULTRARAPID, RAPID, AND POOR DEBRISOQUINE HYDROXYLATORS

      Therapeutic drug monitoring
    40. DALEN P; FRENGELL C; DAHL ML; SJOQVIST F
      QUICK ONSET OF SEVERE ABDOMINAL-PAIN AFTER CODEINE IN AN ULTRARAPID METABOLIZER OF DEBRISOQUINE

      Therapeutic drug monitoring
    41. ROH HK; DAHL ML; JOHANSSON I; INGELMANSUNDBERG M; CHA YN; BERTILSSON L
      DEBRISOQUINE AND S-MEPHENYTOIN HYDROXYLATION PHENOTYPES AND GENOTYPESIN A KOREAN POPULATION

      Pharmacogenetics
    42. DALY AK; FAIRBROTHER KS; ANDREASSEN OA; LONDON SJ; IDLE JR; STEEN VM
      CHARACTERIZATION AND PCR-BASED DETECTION OF 2 DIFFERENT HYBRID CYP2D7P CYP2D6 ALLELES ASSOCIATED WITH THE POOR METABOLIZER PHENOTYPES/

      Pharmacogenetics
    43. LUCOTTE G; TURPIN JC; GERARD N; PANSERAT S; KRISHNAMOORTHY R
      MUTATION FREQUENCIES OF THE CYTOCHROME CYP2D6 GENE IN PARKINSON DISEASE PATIENTS AND IN FAMILIES

      American journal of medical genetics
    44. KRYNETSKII EY
      POLYMORPHISM OF DRUG-METABOLIZING-ENZYMES - GENE STRUCTURE AND ENZYME-ACTIVITY (A REVIEW)

      Molecular biology
    45. BERENBAUM MR; FAVRET C; SCHULER MA
      ON DEFINING KEY INNOVATIONS IN AN ADAPTIVE RADIATION - CYTOCHROME P450S AND PAPILIONIDAE

      The American naturalist
    46. MADSEN H; NIELSEN KK; BROSEN K
      IMIPRAMINE METABOLISM IN RELATION TO THE SPARTEINE AND MEPHENYTOIN OXIDATION POLYMORPHISMS - A POPULATION STUDY

      British journal of clinical pharmacology
    47. ARTHUR H; DAHL ML; SIWERS B; SJOQVIST F
      POLYMORPHIC DRUG-METABOLISM IN SCHIZOPHRENIC-PATIENTS WITH TARDIVE-DYSKINESIA

      Journal of clinical psychopharmacology
    48. KROEMER HK; EICHELBAUM M
      ITS THE GENES, STUPID - MOLECULAR-BASES AND CLINICAL CONSEQUENCES OF GENETIC CYTOCHROME-P450 2D6 POLYMORPHISM

      Life sciences
    49. DAHL ML; JOHANSSON I; BERTILSSON L; INGELMANSUNDBERG M; SJOQVIST F
      ULTRARAPID HYDROXYLATION OF DEBRISOQUINE IN A SWEDISH POPULATION - ANALYSIS OF THE MOLECULAR-GENETIC BASIS

      The Journal of pharmacology and experimental therapeutics
    50. AGUNDEZ JAG; JIMENEZJIMENEZ FJ; LUENGO A; BERNAL ML; MOLINA JA; AYUSO L; VAZQUEZ A; PARRA J; DUARTE J; CORIA F; LADERO JM; ALVAREZ JC; BENITEZ J
      ASSOCIATION BETWEEN THE OXIDATIVE POLYMORPHISM AND EARLY-ONSET OF PARKINSONS-DISEASE

      Clinical pharmacology and therapeutics
    51. EVERT B; GRIESE EU; EICHELBAUM M
      A MISSENSE MUTATION IN EXON-6 OF THE CYP2D6 GENE LEADING TO A HISTIDINE-324 TO PROLINE EXCHANGE IS ASSOCIATED WITH THE POOR METABOLIZER PHENOTYPE OF SPARTEINE

      Naunyn-Schmiedeberg's archives of pharmacology
    52. MEYER UA
      THE MOLECULAR-BASIS OF GENETIC POLYMORPHISMS OF DRUG-METABOLISM

      Journal of Pharmacy and Pharmacology
    53. AGUNDEZ JAG; MARTINEZ C; LEDESMA MC; LADONA MG; LADERO JM; BENITEZ J
      GENETIC-BASIS FOR DIFFERENCES IN DEBRISOQUIN POLYMORPHISM BETWEEN A SPANISH AND OTHER WHITE-POPULATIONS

      Clinical pharmacology and therapeutics
    54. SINDRUP SH; POULSEN L; BROSEN K; ARENDTNIELSEN L; GRAM LF
      ARE POOR METABOLIZERS OF SPARTEINE DEBRISOQUINE LESS PAIN TOLERANT THAN EXTENSIVE METABOLIZERS

      Pain


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/10/20 alle ore 15:52:05